Research programme: endostatin-derived peptide therapeutics - iBio
Alternative Names: E4-Fc; Peptide E4Latest Information Update: 17 Oct 2025
At a glance
- Originator Medical University of South Carolina
- Developer iBio Inc
- Class Angiostatic proteins; Peptides; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 17 Oct 2025 Discontinued - Preclinical for Solid tumours in USA (Parenteral) (iBio pipeline, October 2025)
- 28 Mar 2023 Preclinical trials in Solid tumours in USA (Parenteral) (iBio pipeline, March 2023)
- 28 Mar 2023 Preclinical development is ongoing in USA for Solid tumours